Junge Zhang Acquires 220,000 Shares of Ocugen (NASDAQ:OCGN) Stock

Ocugen (NASDAQ:OCGN) Director Junge Zhang purchased 220,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were bought at an average price of $0.40 per share, for a total transaction of $88,000.00.

Junge Zhang also recently made the following trade(s):

  • On Wednesday, November 27th, Junge Zhang purchased 270,000 shares of Ocugen stock. The stock was bought at an average price of $0.37 per share, with a total value of $99,900.00.
  • On Monday, November 25th, Junge Zhang acquired 115,000 shares of Ocugen stock. The shares were purchased at an average cost of $0.27 per share, with a total value of $31,050.00.
  • On Friday, November 22nd, Junge Zhang acquired 80,000 shares of Ocugen stock. The shares were purchased at an average cost of $0.28 per share, with a total value of $22,400.00.
  • On Monday, November 18th, Junge Zhang acquired 100,000 shares of Ocugen stock. The shares were purchased at an average price of $0.41 per share, for a total transaction of $41,000.00.
  • On Friday, October 11th, Junge Zhang bought 4,000 shares of Ocugen stock. The stock was purchased at an average cost of $1.82 per share, for a total transaction of $7,280.00.
  • On Monday, September 30th, Junge Zhang bought 31,078 shares of Ocugen stock. The stock was purchased at an average price of $3.09 per share, with a total value of $96,031.02.

Shares of NASDAQ:OCGN opened at $0.41 on Friday. The company’s 50 day simple moving average is $1.03. Ocugen has a 1 year low of $0.23 and a 1 year high of $34.80.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.66) earnings per share for the quarter.

A number of equities analysts recently commented on OCGN shares. ValuEngine raised shares of Ocugen from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Chardan Capital assumed coverage on shares of Ocugen in a research report on Wednesday, November 27th. They issued a “buy” rating and a $2.00 price objective on the stock.

About Ocugen

Ocugen, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases.

See Also: Cost of Equity For A Business, Investors

Insider Buying and Selling by Quarter for Ocugen (NASDAQ:OCGN)

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.